Eli Lilly and Company
EIR issued January 17, 2020 · Indianapolis, Indiana
- Inspection
- Jan 6 – Jan 9, 2020
- Investigator
- Myra K. Casey
- Pages
- 12
- FEI number
- 1819470
In short: This is FDA's Establishment Inspection Report (EIR) for Eli Lilly and Company in Indianapolis, Indiana (FEI 1819470), covering the inspection of Jan 6 – Jan 9, 2020. It is the investigator's full narrative of what they examined, who they spoke to and what they found. The investigator was Myra K. Casey.
Inside this inspection report
The investigator's narrative
The full inspection report: what the investigator looked at, who they spoke to and what they found, in their own words.
Get the full EIRThis inspection in context
Myra K. Casey
5 documents · 2002–2020
Cites 314.80(c)(2) (postmarketing reporting of adverse drug experiences) more than any other section. Most of their documents are for sites in Indiana.
The firmEli Lilly and Company history
All 15 documents on file for this site, in date order, with what was cited at each inspection.
Similar documentsMore eirs
Browse other documents of this type.
Questions about this EIR
Who inspected Eli Lilly and Company?
Myra K. Casey is named on this EIR, for the inspection of Jan 6 – Jan 9, 2020. Each investigator has a profile showing what they cite most.
When was Eli Lilly and Company inspected by FDA?
The inspection ran Jan 6 – Jan 9, 2020.
How do I get the full EIR for Eli Lilly and Company?
Download the original PDF from FDA Intel for $550, with no subscription. You also get an invoice PDF with the order.